It’s time to register for the Hepatocyte Research Association (HRA) 11th Annual Meeting at ISSX Orlando: October 20, 2015 2pm – 6pm Hilton Orlando Bonnet Creek Floridian Ballroom G-I This year’s theme is “Next Generation Liver Culture Models: Applications for Industry.” Ajit Dash, Sylvie Klieber and Ed LeCluyse will talk on – Liver tissue engineering […]
Attention All Hepatocyte Fanatics! Read More »
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD). Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Cabozantinib is currently approved
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
